Non-Alcoholic Steatohepatitis Clinical Trials Market
With the rise in NAFLD and NASH cases, the market for Non-Alcoholic Steatohepatitis Clinical Trials Market Shoot: Opportunities Ahead
Non-Alcoholic Steatohepatitis Clinical Trials Market By Study Design, Phase & Region - Forecast 2022-2032
Non-Alcoholic Steatohepatitis Clinical Trials Market Overview
Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis report by Future Market Insights shows that global sales in 2021 were held at US$ 2.5 Bn. With 7%, the projected market growth during 2022 - 2032 is expected to be significantly higher than the historical growth. Phase 3 is expected to be the highest revenue generating for the Non-Alcoholic Steatohepatitis Clinical Trials Market, with a CAGR of around 11.2% during 2022 – 2032.
|
Attribute |
Details |
|
Global Non-Alcoholic Steatohepatitis Clinical Trials Market (2022) |
US$ 2.6 Bn |
|
Global Non-Alcoholic Steatohepatitis Clinical Trials Market (2032) |
US$ 5.1 Bn |
|
Global Non-Alcoholic Steatohepatitis Clinical Trials Market (2022 – 2032) |
7% |
|
North America Non-Alcoholic Steatohepatitis Clinical Trials Market Share (2022) |
40% |
|
U.S. Non-Alcoholic Steatohepatitis Clinical Trials Market (2022) |
US$ 943.3 Mn |
|
Key Companies Profiled |
|
Let us know your requirement to get
100% FREE customization
Revenue of Non-Alcoholic Steatohepatitis Clinical Trials Market from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032
As per the Non-Alcoholic Steatohepatitis Clinical Trials Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of the Non-Alcoholic Steatohepatitis Clinical Trials Market increased at around 6.2% CAGR, wherein, countries such as the U.S., UK, China, and Japan held a significant share in the global market.
Additionally, rising technical developments and the rising prevalence of chronic diseases, the rise in the number of surgical procedures, and the aging population are the key factors driving the growth. Owing to this, Non-Alcoholic Steatohepatitis Clinical Trials Market is projected to grow at a CAGR of 7% over the coming 10 years.
How Non-Alcoholic Steatohepatitis Clinical Trials Market Fared during the Pandemic?
Due to reduced patient participation in clinical studies and supply chain interruptions, trials were halted as a result of the pandemic. However, some organizations were able to finish the studies using virtual participants and COVID-compliant screening. Novartis, for example, completed a phase two trial of a specific substance in non-alcoholic steatohepatitis after the drug was identified as a groundbreaking therapy in the United States. Semaglutide will be initiated in non-alcoholic steatohepatitis (NASH) patients in phase 3a in 2021. Novo Nordisk and Gilead Sciences presented the findings of a phase two proof-of-concept experiment in NASH. NASH is the second-leading cause of liver transplants in the United States. NASH is also linked to the development of hepatocellular carcinoma, according to recent research.
Due to pathologist bias, classifying patients into discrete fibrosis phases in NASH trials can be difficult. Sagimet Biosciences is using digital histopathology in its Stage IIb non-alcoholic steatohepatitis (NASH) experiment to achieve better consistent biopsy analysis. In the case of NASH, digital pathology entails histological imaging of biopsy samples, which are then evaluated using Ai Technology (AI) to detect fibrosis changes. In the Phase IIb FASCINATE-2 trial (NCT04906421), Sagimet is cooperating with HistoIndex, a Singapore-based diagnostic business, to investigate TVB-2640.
PathAI and Summit Clinical Research, each based in the United States, are collaborating to create AI-powered tools for evaluating liver pathology. There are 1,000 MR Elastography (MRE) machines in use around the world, however, they have yet to reach the areas with the highest number of NASH clinical trial participants. Its limitation is the high expense of improving MR elastography. Finally, whether it be in Europe or the United States, converting a machine to MR elastography costs roughly $100,000. The cost of the technology is a barrier to adoption, as are the fact that, despite the fact that MRE scans are much more expensive than ordinary Mris, medical insurance do not currently pay additional reimbursements.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystRegion-wise Analysis
How is the market scenario in different regions of the world for Non-Alcoholic Steatohepatitis Clinical Trials Market?
Over the projected period, the market in Asia Pacific is expected to grow at the fastest rate of 7.6%. The region's expansion is being fueled by the incidence of diabetes, obesity, and the expanding number of deaths caused by these diseases (which is expected to increase 30-fold by 2030). In 2019, NASH cases are expected to account up 20 to 25 percent of all NAFLD cases, with prevalence of approximately from 5.9% (4.8 percent -7.3 percent) inside the general population in Singapore (all ages). The number of prevalent NASH cases is anticipated to increase by 20% in Hong Kong and South Korea, 25% in Taiwan, and 35% in Singapore between 2019 and 2030. The incidence rates of NAFLD in India are similar to global figures.
NASH is present in around 5% of people with NAFLD. There are no standardized NAFLD screening protocols in India. Fatty liver is usually identified primarily on an ultrasound finding and/or elevated liver enzymes as bulk in noncirrhotic NAFLD and NASH patients who remain asymptomatic. Recent technological advances have resulted in the development of newer as well as better image analysis modes for assessing hyperlipidemia and fibrosis, including magnetic resonance-derived proton density fat portion and MR elastography, which are now being used during early-phase NASH trials to assess the liver amount of fat and fibrosis stage. These are available at a few specialized centers; nevertheless, high costs as well as a paucity of reimbursement can limit their use, particularly in clinical studies.
Country-wise Analysis
U.S. Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis
NAFLD is one of the most common chronic liver conditions in the U.S. It is estimated that about 25% of adults in the U.S. have NAFLD and of them, about 20% have NASH. With these alarming statistics, the Non-Alcoholic Steatohepatitis Clinical Trials market in the U.S. is expected to reach a valuation of US$ 1.9 Bn by 2032, at a CAGR of 7.5% during 2022 – 2032.
U.K. Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis
A Study indicates that one in eight adults in the U.K. may have NASH. It indicates that the prevalence of non-alcohol-related steatohepatitis among UK adults could be as high as 12%. Owing to these figures, the market for Non-Alcoholic Steatohepatitis Clinical Trials Market in the U.K. stood at around US$ 100 Mn in 2021. With a CAGR of 7.6%, the market is projected to reach a valuation of US$ 222.2 Mn by 2032.
Japan Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis
The prevalence of NAFLD in the Japanese population rose from 12.6 – 12.9% of the population in the early 1990s to 24.6 – 34.7% of the population in the early 2000s. At present, the prevalence of NASH in Japan is estimated to be 1.9 – 2.7%. In 2021, Non-Alcoholic Steatohepatitis Clinical Trials Market in Japan was held at US$ 116 Mn, which is expected to swell to US$ 211 Mn by 2032.
South Korea Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis
The market for Non-Alcoholic Steatohepatitis Clinical Trials in South Korea accounted for US$ 48.3 Mn. With an absolute dollar opportunity of around US$ 50 Mn during 2022 – 2032, the market is projected to reach a valuation of US$ 102 Mn by 2032.
An unified Market Research Subscription Platform, built for today’s disparate research needs.
Category-wise Analysis
What are the insights of different phases in the Non-Alcoholic Steatohepatitis Clinical Trials Market?
In 2021, phase III clinical trials accounted for around 40% of global sales. Phase III studies are known for their high expenditures. A single phase III study, for example, costs around US$ 100 million. As a result, the failure of these studies has a significant economic impact just on sponsors. A Phase III trial collects further information on the drug's safety and efficacy by evaluating additional populations and doses, as well as combining it with other medications. Intelligent, quantitative radiography in association with other diagnostic markers for NASH is the most effective and cost-effective technique to identify and follow NASH patients for clinical trials. All Phase 3 NASH studies must include at least two people, according to existing FDA standards.
What is the market scenario of different study designs in the Non-Alcoholic Steatohepatitis Clinical Trials Market?
In 2021, the interventional category led the market with a share of around 45.5%. There were 84 active intervention studies involving patients enrolled in December 2019 to examine the treatment effectiveness of NASH treatments. The bulk of these trials is looking into innovative medications as targeted therapies, with some looking into NASH treatment in combination. The FDA and the EMA recognized that a histopathological study of cell samples taken from a liver biopsy is the most reliable technique to diagnose NASH. Biomarkers are a subject of controversy between the European Medicines Agency (EMA) and the Food and Drug Administration (FDA).
The FDA highly advises using a biomarker signature technique in phase 2 of a trial. The EMA does neither prohibit nor require the implementation of such a method in stage 2, but it does not require it. Intervention trialists are all in high demand as a result. During the projection period, expanded access trials, also called compassionate use tests, are predicted to rise at the fastest CAGR of 7.7%. Patients with serious illness conditions may be able to receive treatment even in a clinical trial if no satisfactory medicines are available. Increased development in NASH clinical trial methodologies is projected to drive the expanded entry trials market.
Competitive Analysis
Some of the key companies operating in the Non-Alcoholic Steatohepatitis Clinical Trials Market include Pfizer Inc., Novartis AG, Icon Plc, LabCorp, Allergan Plc, Cadila Healthcare Ltd., Shire Plc, Eli Lilly, Novo Nordisk, Gilead Sciences Inc., Glaxosmith Kline, and Arrowhead Pharmaceuticals.
Market participants are pursuing a number of strategic activities, including new partnership agreements, collaborations, mergers and acquisitions, geographic expansion, and strengthening their services and production facilities in order to gain a competitive advantage.
Some of the key developments in the Non-Alcoholic Steatohepatitis Clinical Trials Market are:
- In March 2021, Gilead Technologies, Inc. and Nordisk Nordisk announced that their non-alcoholic steatohepatitis study alliance had been enlarged. The firms would conduct a Phase 2b double-blind, placebo-controlled research in people with compensated cirrhosis (F4) due to NASH to examine the safety and efficacy of Novo Nordisk's semaglutide, a GLP-1 receptor agonist.
- In November 2021, with a US$ 1 Bn asset transaction with Arrowhead Pharmaceuticals, GlaxoSmithKline announced that it is undertaking its first effort to address the fatty liver illness known as non - alcoholic steatohepatitis (NASH). With a US$ 80 million licence agreement with Pliant Therapeutics in October 2019, Novartis acquired another non-alcoholic steatohepatitis pharmaceutical candidate to its pipeline.
- In January 2021, Terns Pharmaceuticals launched NASH prospects in clinical development. Following leasing three NASH candidates, the business received an investment of US$ 87 million from Eli Lilly and Deerfield Management.
Market Segments Covered in Non-Alcoholic Steatohepatitis Clinical Trials Market Analysis
By Study Design:
- Interventional
- Observational
- Expanded Access
By Phase:
- Phase 1
- Phase 2
- Phase 3
- Phase 4
By Region:
- North America
- Latin America
- APAC
- MEA
- Europe
Frequently Asked Questions
The Non-Alcoholic Steatohepatitis Clinical Trials Market is worth more than US$ 2.6 Bn at present.
The value of the Non-Alcoholic Steatohepatitis Clinical Trials Market is projected to increase at a CAGR of around 7% during 2022 – 2032.
The value of the Non-Alcoholic Steatohepatitis Clinical Trials Market increased at a CAGR of around 6.2% during 2017– 2021.
Phase III Non-Alcoholic Steatohepatitis Clinical Trials are expected to get augmented in the forthcoming years.
The top 5 countries are US, UK, China, Japan and South Korea
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Summary of Statistics
1.3. Key Market Characteristics & Attributes
1.4. Fact.MR Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Risks and Trends Assessment
3.1. Risk Assessment
3.1.1. COVID-19 Crisis and Impact on Market
3.1.2. COVID-19 Impact Benchmark with Previous Crisis
3.1.3. Impact on Market Value (US$ Mn)
3.1.4. Assessment by Key Countries
3.1.5. Assessment by Key Market Segments
3.1.6. Action Points and Recommendation for Suppliers
3.2. Key Trends Impacting the Market
3.3. Formulation and Product Development Trends
4. Market Background and Foundation Data Points
4.1. Global Market (US$ Mn)
4.2. Market Opportunity Assessment (US$ Mn)
4.2.1. Total Available Market
4.2.2. Serviceable Addressable Market
4.2.3. Serviceable Obtainable Market
4.3. Market Scenario Forecast
4.3.1. Demand in optimistic Scenario
4.3.2. Demand in Likely Scenario
4.3.3. Demand in Conservative Scenario
4.4. Investment Feasibility Analysis
4.4.1. Investment in Established Markets
4.4.1.1. In Short Term
4.4.1.2. In Long Term
4.4.2. Investment in Emerging Markets
4.4.2.1. In Short Term
4.4.2.2. In Long Term
4.5. Forecast Factors - Relevance & Impact
4.5.1. Top Companies Historical Growth
4.5.2. Global Market Growth
4.5.3. Adoption Rate, By Country
4.6. Market Dynamics
4.6.1. Market Driving Factors and Impact Assessment
4.6.2. Prominent Market Challenges and Impact Assessment
4.6.3. Market Opportunities
4.6.4. Prominent Trends in the Global Market & Their Impact Assessment
5. Key Success Factors
5.1. Manufacturers’ Focus on Low Penetration High Growth Markets
5.2. Banking on with Segments High Incremental Opportunity
5.3. Peer Benchmarking
6. Global Market Demand Analysis 2017-2021 and Forecast, 2022-2032
6.1. Historical Market Analysis, 2017-2021
6.2. Current and Future Market Projections, 2022-2032
6.3. Y-o-Y Growth Trend Analysis
7. Global Market Value Analysis 2017-2021 and Forecast, 2022-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2017-2021
7.2. Current and Future Market Value (US$ Mn) Projections, 2022-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Study Design
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Study Design, 2017-2021
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Study Design, 2022-2032
8.3.1. Interventional
8.3.2. Observational
8.3.3. Expanded Access
8.4. Market Attractiveness Analysis By Study Design
9. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Phase
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Phase, 2017-2021
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Phase, 2022-2032
9.3.1. Phase 1
9.3.2. Phase 2
9.3.3. Phase 3
9.3.4. Phase 4
9.4. Market Attractiveness Analysis By Phase
10. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
10.1. Introduction
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2017-2021
10.3. Current Market Size (US$ Mn) & Analysis and Forecast By Region, 2022-2032
10.3.1. North America
10.3.2. Latin America
10.3.3. Europe
10.3.4. Asia Pacific
10.3.5. Middle East and Africa (MEA)
10.4. Market Attractiveness Analysis By Region
11. North America Market Analysis 2017-2021 and Forecast 2022-2032
11.1. Introduction
11.2. Pricing Analysis
11.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
11.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
11.4.1. By Country
11.4.1.1. U.S.
11.4.1.2. Canada
11.4.1.3. Rest of North America
11.4.2. By Study Design
11.4.3. By Phase
11.5. Market Attractiveness Analysis
11.5.1. By Country
11.5.2. By Study Design
11.5.3. By Phase
12. Latin America Market Analysis 2017-2021 and Forecast 2022-2032
12.1. Introduction
12.2. Pricing Analysis
12.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
12.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
12.4.1. By Country
12.4.1.1. Brazil
12.4.1.2. Mexico
12.4.1.3. Rest of Latin America
12.4.2. By Study Design
12.4.3. By Phase
12.5. Market Attractiveness Analysis
12.5.1. By Country
12.5.2. By Study Design
12.5.3. By Phase
13. Europe Market Analysis 2017-2021 and Forecast 2022-2032
13.1. Introduction
13.2. Pricing Analysis
13.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
13.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
13.4.1. By Country
13.4.1.1. Germany
13.4.1.2. France
13.4.1.3. U.K.
13.4.1.4. Italy
13.4.1.5. Benelux
13.4.1.6. Nordic Countries
13.4.1.7. Rest of Europe
13.4.2. By Study Design
13.4.3. By Phase
13.5. Market Attractiveness Analysis
13.5.1. By Country
13.5.2. By Study Design
13.5.3. By Phase
14. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032
14.1. Introduction
14.2. Pricing Analysis
14.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
14.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
14.4.1. By Country
14.4.1.1. China
14.4.1.2. Japan
14.4.1.3. South Korea
14.4.1.4. Rest of Asia Pacific
14.4.2. By Study Design
14.4.3. By Phase
14.5. Market Attractiveness Analysis
14.5.1. By Country
14.5.2. By Study Design
14.5.3. By Phase
15. Middle East and Africa Market Analysis 2017-2021 and Forecast 2022-2032
15.1. Introduction
15.2. Pricing Analysis
15.3. Historical Market Value (US$ Mn) Trend Analysis By Market Taxonomy, 2017-2021
15.4. Market Value (US$ Mn) & Forecast By Market Taxonomy, 2022-2032
15.4.1. By Country
15.4.1.1. GCC Countries
15.4.1.2. South Africa
15.4.1.3. Turkey
15.4.1.4. Rest of Middle East and Africa
15.4.2. By Study Design
15.4.3. By Phase
15.5. Market Attractiveness Analysis
15.5.1. By Country
15.5.2. By Study Design
15.5.3. By Phase
16. Key Countries Market Analysis 2017-2021 and Forecast 2022-2032
16.1. Introduction
16.1.1. Market Value Proportion Analysis, By Key Countries
16.1.2. Global Vs. Country Growth Comparison
16.2. US Market Analysis
16.2.1. Value Proportion Analysis by Market Taxonomy
16.2.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.2.2.1. By Study Design
16.2.2.2. By Phase
16.3. Canada Market Analysis
16.3.1. Value Proportion Analysis by Market Taxonomy
16.3.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.3.2.1. By Study Design
16.3.2.2. By Phase
16.4. Mexico Market Analysis
16.4.1. Value Proportion Analysis by Market Taxonomy
16.4.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.4.2.1. By Study Design
16.4.2.2. By Phase
16.5. Brazil Market Analysis
16.5.1. Value Proportion Analysis by Market Taxonomy
16.5.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.5.2.1. By Study Design
16.5.2.2. By Phase
16.6. Germany Market Analysis
16.6.1. Value Proportion Analysis by Market Taxonomy
16.6.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.6.2.1. By Study Design
16.6.2.2. By Phase
16.7. France Market Analysis
16.7.1. Value Proportion Analysis by Market Taxonomy
16.7.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.7.2.1. By Study Design
16.7.2.2. By Phase
16.8. Italy Market Analysis
16.8.1. Value Proportion Analysis by Market Taxonomy
16.8.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.8.2.1. By Study Design
16.8.2.2. By Phase
16.9. BENELUX Market Analysis
16.9.1. Value Proportion Analysis by Market Taxonomy
16.9.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.9.2.1. By Study Design
16.9.2.2. By Phase
16.10. UK Market Analysis
16.10.1. Value Proportion Analysis by Market Taxonomy
16.10.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.10.2.1. By Study Design
16.10.2.2. By Phase
16.11. Nordic Countries Market Analysis
16.11.1. Value Proportion Analysis by Market Taxonomy
16.11.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.11.2.1. By Study Design
16.11.2.2. By Phase
16.12. China Market Analysis
16.12.1. Value Proportion Analysis by Market Taxonomy
16.12.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.12.2.1. By Study Design
16.12.2.2. By Phase
16.13. Japan Market Analysis
16.13.1. Value Proportion Analysis by Market Taxonomy
16.13.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.13.2.1. By Study Design
16.13.2.2. By Phase
16.14. South Korea Market Analysis
16.14.1. Value Proportion Analysis by Market Taxonomy
16.14.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.14.2.1. By Study Design
16.14.2.2. By Phase
16.15. GCC Countries Market Analysis
16.15.1. Value Proportion Analysis by Market Taxonomy
16.15.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.15.2.1. By Study Design
16.15.2.2. By Phase
16.16. South Africa Market Analysis
16.16.1. Value Proportion Analysis by Market Taxonomy
16.16.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.16.2.1. By Study Design
16.16.2.2. By Phase
16.17. Turkey Market Analysis
16.17.1. Value Proportion Analysis by Market Taxonomy
16.17.2. Value & Analysis and Forecast by Market Taxonomy, 2017-2032
16.17.2.1. By Study Design
16.17.2.2. By Phase
16.17.3. Competition Landscape and Player Concentration in the Country
17. Market Structure Analysis
17.1. Market Analysis by Tier of Companies
17.2. Market Concentration
17.3. Market Share Analysis of Top Players
17.4. Market Presence Analysis
17.4.1. By Regional footprint of Players
17.4.2. Product footprint by Players
18. Competition Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Competition Deep Dive
18.3.1. Pfizer Inc.
18.3.1.1. Overview
18.3.1.2. Product Portfolio
18.3.1.3. Sales Footprint
18.3.1.4. Strategy Overview
18.3.2. Novartis AG
18.3.3. Icon Plc
18.3.4. LabCorp
18.3.5. Allergan Plc
18.3.6. Cadila Healthcare Ltd.
18.3.7. Shire Plc
18.3.8. Eli Lilly
18.3.9. Novo Nordisk
18.3.10. Gilead Sciences Inc.
18.3.11. Glaxosmith Kline
18.3.12. Arrowhead Pharmaceuticals
19. Assumptions and Acronyms Used
20. Research Methodology
Let us know your requirement to get
100% FREE customization
List of Tables
Table 1: Global Market Value (US$ Mn), By Study Design, 2017 – 2021
Table 2: Global Market Value (US$ Mn), By Study Design, 2022 – 2032
Table 3: Global Market Value (US$ Mn), By Phase, 2017 – 2021
Table 4: Global Market Value (US$ Mn), By Phase, 2022 – 2032
Table 5: Global Market, By Region, 2017 – 2021
Table 6: Global Market, By Region, 2022 – 2032
Table 7: North America Market Value (US$ Mn), By Study Design, 2017 – 2021
Table 8: North America Market Value (US$ Mn), By Study Design, 2022 – 2032
Table 9: North America Market Value (US$ Mn), By Phase, 2017 – 2021
Table 10: North America Market Value (US$ Mn), By Phase, 2022 – 2032
Table 11: North America Market, By Country, 2017 – 2021
Table 12: North America Market, By Country, 2022 – 2032
Table 13: Latin America Market Value (US$ Mn), By Study Design, 2017 – 2021
Table 14: Latin America Market Value (US$ Mn), By Study Design, 2022 – 2032
Table 15: Latin America Market Value (US$ Mn), By Phase, 2017 – 2021
Table 16: Latin America Market Value (US$ Mn), By Phase, 2022 – 2032
Table 17: Latin America Market, By Country, 2017 – 2021
Table 18: Latin America Market, By Country, 2022 – 2032
Table 19: Europe Market Value (US$ Mn), By Study Design, 2017 – 2021
Table 20: Europe Market Value (US$ Mn), By Study Design, 2022 – 2032
Table 21: Europe Market Value (US$ Mn), By Phase, 2017 – 2021
Table 22: Europe Market Value (US$ Mn), By Phase, 2022 – 2032
Table 23: Europe Market, By Country, 2017 – 2021
Table 24: Europe Market, By Country, 2022 – 2032
Table 25: Asia Pacific Market Value (US$ Mn), By Study Design, 2017 – 2021
Table 26: Asia Pacific Market Value (US$ Mn), By Study Design, 2022 – 2032
Table 27: Asia Pacific Market Value (US$ Mn), By Phase, 2017 – 2021
Table 28: Asia Pacific Market Value (US$ Mn), By Phase, 2022 – 2032
Table 29: Asia Pacific Market, By Country, 2017 – 2021
Table 30: Asia Pacific Market, By Country, 2022 – 2032
Table 31: MEA Market Value (US$ Mn), By Study Design, 2017 – 2021
Table 32: MEA Market Value (US$ Mn), By Study Design, 2022 – 2032
Table 33: MEA Market Value (US$ Mn), By Phase, 2017 – 2021
Table 34: MEA Market Value (US$ Mn), By Phase, 2022 – 2032
Table 35: MEA Market, By Country, 2017 – 2021
Table 36: MEA Market, By Country, 2022 – 2032
Table 37: Global Market Incremental $ Opportunity, By Study Design, 2017 - 2021
Table 38: Global Market Incremental $ Opportunity, By Phase, 2022 – 2032
Table 39: Global Market Incremental $ Opportunity, By Region, 2022 – 2032
Table 40: North America Market Incremental $ Opportunity, By Study Design, 2017 - 2021
Table 41: North America Market Incremental $ Opportunity, By Phase, 2022 – 2032
Table 42: North America Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 43: Latin America Market Incremental $ Opportunity, By Study Design, 2017 - 2021
Table 44: Latin America Market Incremental $ Opportunity, By Phase, 2022 – 2032
Table 45: Latin America Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 46: Europe Market Incremental $ Opportunity, By Study Design, 2017 - 2021
Table 47: Europe Market Incremental $ Opportunity, By Phase, 2022 – 2032
Table 48: Europe Market Incremental $ Opportunity, By Country, 2022 - 2032
Table 49: Asia Pacific Market Incremental $ Opportunity, By Study Design, 2017 - 2021
Table 50: Asia Pacific Market Incremental $ Opportunity, By Phase, 2022 – 2032
Table 51: Asia Pacific Market Incremental $ Opportunity, By Country, 2022 – 2032
Table 52: MEA Market Incremental $ Opportunity, By Study Design, 2017 - 2021
Table 53: MEA Market Incremental $ Opportunity, By Phase, 2022 – 2032
Table 54: MEA Market Incremental $ Opportunity, By Country, 2022 - 2032
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 2: Global Market Absolute $ Historical Gain (2017 - 2021) and Opportunity (2022 – 2032), US$ Mn
Figure 3: Global Market Share, By Study Design, 2022 & 2032
Figure 4: Global Market Y-o-Y Growth Projections, By Study Design – 2022-2032
Figure 5: Global Market Attractiveness Index, By Study Design – 2022-2032
Figure 6: Global Market Share, By Phase, 2022 & 2032
Figure 7: Global Market Y-o-Y Growth Projections, By Phase – 2022-2032
Figure 8: Global Market Attractiveness Index, By Phase – 2022-2032
Figure 9: Global Market Share, By Region, 2022 & 2032
Figure 10: Global Market Y-o-Y Growth Projections, By Region – 2022-2032
Figure 11: Global Market Attractiveness Index, By Region – 2022-2032
Figure 12: North America Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 13: North America Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 14: North America Market Share, By Study Design, 2022 & 2032
Figure 15: North America Market Y-o-Y Growth Projections, By Study Design – 2022-2032
Figure 16: North America Market Attractiveness Index, By Study Design – 2022-2032
Figure 17: North America Market Share, By Phase, 2022 & 2032
Figure 18: North America Market Y-o-Y Growth Projections, By Phase – 2022-2032
Figure 19: North America Market Attractiveness Index, By Phase – 2022-2032
Figure 20: North America Market Share, By Country, 2022 & 2032
Figure 21: North America Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 22: North America Market Attractiveness Index, By Country – 2022-2032
Figure 23: Latin America Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 24: Latin America Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 25: Latin America Market Share, By Study Design, 2022 & 2032
Figure 26: Latin America Market Y-o-Y Growth Projections, By Study Design – 2022-2032
Figure 27: Latin America Market Attractiveness Index, By Study Design – 2022-2032
Figure 28: Latin America Market Share, By Phase, 2022 & 2032
Figure 29: Latin America Market Y-o-Y Growth Projections, By Phase – 2022-2032
Figure 30: Latin America Market Attractiveness Index, By Phase – 2022-2032
Figure 31: Latin America Market Share, By Country, 2022 & 2032
Figure 32: Latin America Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 33: Latin America Market Attractiveness Index, By Country – 2022-2032
Figure 34: Europe Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 35: Europe Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 36: Europe Market Share, By Study Design, 2022 & 2032
Figure 37: Europe Market Y-o-Y Growth Projections, By Study Design – 2022-2032
Figure 38: Europe Market Attractiveness Index, By Study Design – 2022-2032
Figure 39: Europe Market Share, By Phase, 2022 & 2032
Figure 40: Europe Market Y-o-Y Growth Projections, By Phase – 2022-2032
Figure 41: Europe Market Attractiveness Index, By Phase – 2022-2032
Figure 42: Europe Market Share, By Country, 2022 & 2032
Figure 43: Europe Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 44: Europe Market Attractiveness Index, By Country – 2022-2032
Figure 45: MEA Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 46: MEA Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 47: MEA Market Share, By Study Design, 2022 & 2032
Figure 48: MEA Market Y-o-Y Growth Projections, By Study Design – 2022-2032
Figure 49: MEA Market Attractiveness Index, By Study Design – 2022-2032
Figure 50: MEA Market Share, By Phase, 2022 & 2032
Figure 51: MEA Market Y-o-Y Growth Projections, By Phase – 2022-2032
Figure 52: MEA Market Attractiveness Index, By Phase – 2022-2032
Figure 53: MEA Market Share, By Country, 2022 & 2032
Figure 54: MEA Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 55: MEA Market Attractiveness Index, By Country – 2022-2032
Figure 56: Asia Pacific Market Value (US$ Mn) and Year-on-Year Growth, 2017-2032
Figure 57: Asia Pacific Market Absolute $ Opportunity Historical (2017 - 2021) and Forecast Period (2022 – 2032), US$ Mn
Figure 58: Asia Pacific Market Share, By Study Design, 2022 & 2032
Figure 59: Asia Pacific Market Y-o-Y Growth Projections, By Study Design – 2022-2032
Figure 60: Asia Pacific Market Attractiveness Index, By Study Design – 2022-2032
Figure 61: Asia Pacific Market Share, By Phase, 2022 & 2032
Figure 62: Asia Pacific Market Y-o-Y Growth Projections, By Phase – 2022-2032
Figure 63: Asia Pacific Market Attractiveness Index, By Phase – 2022-2032
Figure 64: Asia Pacific Market Share, By Country, 2022 & 2032
Figure 65: Asia Pacific Market Y-o-Y Growth Projections, By Country – 2022-2032
Figure 66: Asia Pacific Market Attractiveness Index, By Country – 2022-2032
Figure 67: US Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 68: US Market Share, By Study Design, 2021
Figure 69: US Market Share, By Phase, 2021
Figure 70: Canada Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 71: Canada Market Share, By Study Design, 2021
Figure 72: Canada Market Share, By Phase, 2021
Figure 73: Brazil Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 74: Brazil Market Share, By Study Design, 2021
Figure 75: Brazil Market Share, By Phase, 2021
Figure 76: Mexico Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 77: Mexico Market Share, By Study Design, 2021
Figure 78: Mexico Market Share, By Phase, 2021
Figure 79: Germany Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 80: Germany Market Share, By Study Design, 2021
Figure 81: Germany Market Share, By Phase, 2021
Figure 82: U.K. Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 83: U.K. Market Share, By Study Design, 2021
Figure 84: U.K. Market Share, By Phase, 2021
Figure 85: France Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 86: France Market Share, By Study Design, 2021
Figure 87: France Market Share, By Phase, 2021
Figure 88: Italy Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 89: Italy Market Share, By Study Design, 2021
Figure 90: Italy Market Share, By Phase, 2021
Figure 91: BENELUX Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 92: BENELUX Market Share, By Study Design, 2021
Figure 93: BENELUX Market Share, By Phase, 2021
Figure 94: Nordic Countries Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 95: Nordic Countries Market Share, By Study Design, 2021
Figure 96: Nordic Countries Market Share, By Phase, 2021
Figure 97: China Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 98: China Market Share, By Study Design, 2021
Figure 99: China Market Share, By Phase, 2021
Figure 100: Japan Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 101: Japan Market Share, By Study Design, 2021
Figure 102: Japan Market Share, By Phase, 2021
Figure 103: South Korea Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 104: South Korea Market Share, By Study Design, 2021
Figure 105: South Korea Market Share, By Phase, 2021
Figure 106: GCC Countries Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 107: GCC Countries Market Share, By Study Design, 2021
Figure 108: GCC Countries Market Share, By Phase, 2021
Figure 109: South Africa Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 110: South Africa Market Share, By Study Design, 2021
Figure 111: South Africa Market Share, By Phase, 2021
Figure 112: Turkey Market Value (US$ Mn) and Forecast, 2022 - 2032
Figure 113: Turkey Market Share, By Study Design, 2021
Figure 114: Turkey Market Share, By Phase, 2021
Need specific information?
Request CustomizationExplore Healthcare Insights
View Reports
